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Abstract
The nervous system is a target for physiological and protective effects of neuroactive steroids. Consequently, the assessment of their levels in
nervous structures under physiological and pathological conditions is a top priority. To this aim, identification and quantification of pregnenolone
(PREG), progesterone (PROG), dihydroprogesterone (DHP), tetrahydroprogesterone (THP), testosterone (T), dihydrotestosterone (DHT), 5a-
androstan-3a, 17b-diol (3a-diol), 17a- and 17b-estradiol (17a-E and 17b-E) by liquid chromatography and tandem mass spectrometry (LC–MS/
MS) has been set up. After validation, this method was applied to determine the levels of neuroactive steroids in central (i.e., cerebral cortex,
cerebellum and spinal cord) and peripheral (i.e., brachial nerve) nervous system of control and diabetic rats. In controls only the brachial nerve had
detectable levels of all these neuroactive steroids. In contrast, 17a-E in cerebellum, 17a-E, 17b-E, DHP and THP in cerebral cortex, and 17a-E,
17b-E and DHP in spinal cord were under the detection limit. Diabetes, induced by injection with streptozotocin, strongly affected the levels of
some neuroactive steroids. In particular, the levels of PREG, PROG and T in cerebellum, of PROG, T and 3a-diol in cerebral cortex, of PROG,
DHTand 3a-diol in spinal cord and of PREG, DHP, THP, T, DHTand 3a-diol in brachial nerve were significantly decreased. In conclusion, the data
here reported demonstrate that the LC–MS/MS method allows the assessment of neuroactive steroids in the nervous system with high sensitivity
and specificity and that diabetes strongly affects their levels, providing a further basis for new therapeutic tools based on neuroactive steroids aimed
at counteracting diabetic neuropathy.
# 2007 Published by Elsevier Ltd.
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1. Introduction
One important complication of diabetes is the damage that
may occur at the level of the nervous system. Diabetic
peripheral neuropathy occurs in 60–70% of patients affected by
type I and type II diabetes and, as described both in human and
in animal models. For instance streptozotocin (STZ)-induced
neuropathy, is associated with a spectrum of functional (e.g.,
nerve conduction velocity, expression of myelin proteins,
Na+,K+-ATPase activity, nociceptive threshold, etc.) and53
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spectrometry in central and peripheral nervous system: Effect of diabetstructural (e.g., axonal degeneration, paranodal demyelination
and loss of myelinated fibers) changes in peripheral nerves
(Yagihashi, 1997; Biessels et al., 1999; Bianchi et al., 2004;
Veiga et al., 2006; Leonelli et al., 2007). Moreover, the impact
of diabetes on the central nervous system (CNS) is well
recognized. Neurophysiological and structural changes at the
level of cerebral areas, such as hypothalamus, cerebral cortex,
cerebellum and hippocampus, are associated with cognitive
deficits and increased risk of dementia, stroke, cerebrovascular
and Alzheimer disease and psychiatric disorders, such as
depression and eating disorders (Gispen and Biessels, 2000;
Jacobson et al., 2002; Sima et al., 2004; van Harten et al., 2006).
It is well known that neuroactive steroids, like for instance
pregnenolone (PREG), progesterone (PROG), and its deriva-euroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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Table 1
Analytical parameters
Precursor
ions
Transition
monitored
RRT IS Segment
D4-17b-E 259 161 1 – 1
17b-E 255 133, 159 1.01 D4-17b-E 1
17a-E 255 133, 159 1.08 D4-17b-E 1
T 289 97, 109 1.07 D4-17b-E 1
D9-PROG 324 100 1 – 2
PROG 315 97, 109 1.02 D9-PROG 2
DHT 291 255 0.89 D9-PROG 2
3a-Diol 257 121, 135, 147,
161, 175
1.08 D9-PROG 2
D4-PREG 303 175 1 – 3
PREG 299 159, 199 1.01 D4-PREG 3
DHP 299 189 1.05 D4-PREG 3
THP 301 159, 173, 187 1.27 D4-PREG 3
RRT: relative retention time (calculated against the IS monitored in the
corresponding segment); IS: internal standard.
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tives dihydroprogesterone (DHP) and tetrahydroprogesterone
(THP), testosterone (T) and its derivatives dihydrotestosterone
(DHT) and 5a-androstan-3a, 17b-diol (3a-diol), and estrogens
regulate several physiological processes in neurons and glial
cells of the peripheral nervous system (PNS) and CNS (Melcangi
et al., 2001, 2002, 2005; Garcia-Segura and Melcangi, 2006).
Moreover, recent observations obtained in our and other
laboratories have indicated that these neuroactive steroids exert
protective effects in several experimental models of neurode-
generation (Lapchak and Araujo, 2001; Azcoitia et al., 2003;
McCullogh and Hurn, 2003; Ciriza et al., 2004; Griffin et al.,
2004), including diabetic neuropathy (Veiga et al., 2006; Leonelli
et al., 2007; Saravia et al., 2006). Interestingly, the impact of
diabetes is also evident on steroid levels. Indeed, several
observations have shown dysfunction in the reproductive axis
associated with diabetes, with modifications of sex steroid
plasma levels (El’tseva et al., 1993; Sudha et al., 2000; Tanaka
et al., 2001; van Dam et al., 2003; Salonia et al., 2006). Moreover,
we have recently observed that STZ-induced diabetes causes
plasma PROG levels to drop steeply in male rats (Leonelli et al.,
2007). Furthermore, altered levels of neuroactive steroids occur
not only in plasma but also in nervous tissues. It has been recently
reported that an increase of PROG biosynthesis concomitant with
a decrease of formation of its metabolite, THP, occurs in the
spinal cord of rats with STZ-induced diabetes (Saredi et al.,
2005). This single report is highly relevant because the
modifications of the levels of steroids in neural tissue with
diabetes may potentially increase, decrease and/or be the
consequence of local pathological damage and may affect the
result of therapies based on neuroactive steroids. Consequently, it
is extremely important to determine the levels of neuroactive
steroids in central and peripheral nervous structures and to assess
whether these levels are modified by diabetes.
With this aim, an analytical method based on liquid
chromatography and tandem mass spectrometry (LC–MS/MS)
for the identification and quantification of PREG, PROG, DHP,
THP, T, DHT, 3a-diol, 17a- and 17b-estradiol (17a-E and 17b-
E) has been set up. After validation of the LC–MS/MS
procedure, this method was applied to the identification and
quantitative determination of the neuroactive steroids men-
tioned above in CNS structures, such as cerebral cortex,
cerebellum and spinal cord, and in a peripheral nerve, such as
brachial nerve, of control and STZ-treated rats.
2. Experimental procedures
2.1. Materials
5-Pregnen-3b-ol-20-one (PREG), progesterone (PROG), 5a-pregnane-3,
20-dione (DHP), 3a-hydroxy-5a-pregnen-20-one (THP), testosterone (T), 5a-
androstane-17b-ol-3-one (DHT), 5a-androstane-3a, 17b-diol (3a-diol), 17a-
and 17b-estradiol (17a-E and 17b-E), were purchased from Sigma–Aldrich.
17,21,21,21-D4 PREG (D4-PREG) was kindly synthesized by Dr. P. Ferra-
boschi (Deptartment of Medical Chemistry, Biochemistry and Biotechnology,
University of Milano, Italy); 2,2,4,6,6-17a,21,21,21-D9-PROG (D9-PROG)
was obtained from Medical Isotopes (Pelham, NH, USA) and 2,4,16,16-D4-
17b-E (D4-17b-E) from CDN Isotope Pointe-Claire (Que., Canada). SPE
cartridges (Discovery DS-C18 500 mg) were from Supelco, Italy. All solvents
and reagents were HPLC grade (Sigma–Aldrich, Italy).Please cite this article in press as: Caruso, D. et al., Evaluation of n
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2.2. LC–MS/MS analysis
Positive atmospheric pressure chemical ionization (APCI+) experiments
were performed using a linear ion trap-mass spectrometer (LTQ, ThermoElec-
tron Co., San Jose, CA, USA) equipped with a Surveyor liquid chromatography
(LC) Pump Plus and a Surveyor Autosampler Plus (ThermoElectron Co., San
Jose, CA, USA).
The LC mobile phases were (A) H2O/0.1% formic acid and (B) methanol
(MeOH)/0.1% formic acid. The gradient (flow rate 1 ml/min) was as follows: T0
60%A, T4.5 60%A, T5 40%A, T8 40%A, T45 30%A, T46 10%A, T54 10%A, T55
60%A, T65 60%A. The split valve was set at 0–10 min to waste, 10–50 min to
source and 50–65 min to waste. The Inertsil ODS-2 RP-C18 column (5 mm,
150 mm  4.6 mm i.d.; GL Sciences Inc., Japan) was maintained at 40 8C. The
injection volume was 25 ml and the injector needle was washed with MeOH/
water 1/1 (v/v). Peaks of the LC–MS/MS were evaluated using a Dell work-
station by means of the software Excalibur1 release 2.0 SR2 (ThermoElectron
Co, San Jose, CA, USA).
The mass spectrometer was operated in the positive ion mode with the
atmospheric pressure chemical ionization (APCI) source using nitrogen as sheath,
auxiliary and sweep gas at flow rates of 23, 8, 2 (arbitrary units), respectively.
Other ion-source parameters: vaporizer temperature 450 8C, ion-source collision-
energy (SID) 20 V, capillary temperature 275 8C. The mass spectrometer was
employed in MS/MS mode using helium as collision gas. The relative collision-
energy was set at 35% for 17a-E, 17b-E, D4-17b-E, 3a-diol and at 35% using the
Wide Band Activation mode (ThermoElectron Co., USA) for all the other steroids.
Samples were analyzed employing the transitions reported in Table 1.
2.3. Study design and sample preparation
Two-month-old male Sprague–Dawley rats, Crl:CD BR (Charles River,
Italy) were housed in the animal quarters of the Department of Endocrinology at
the University of Milan with controlled temperature and humidity. The light
schedule was 14 h light and 10 h dark (lights on at 6:30 h). The animals were
handled following the European Union Normative (Council Directive 86/609/
EEC guidelines), with the approval of our Institutional Animal Use and Care
Committees. Rats were randomly divided into two groups (control and dia-
betes).
Diabetes was induced by a single injection into the tail vein of freshly
prepared STZ (65 mg/kg; Sigma, Italy) in citrate buffer 0.09 M pH 4.8. Control
animals were injected with 0.09 M citrate buffer at pH 4.8. Hyperglycemia was
confirmed 48 h after STZ injection by measuring tail vein blood glucose levels
using a Glucomen tester (Menarini, Italy). Only animals with mean plasma
glucose levels above 300 mg/dl were classified as diabetic. Three months after
the diabetes induction, rats were sacrificed and cerebral cortex, cerebellum,
spinal cord and brachial nerve were collected, weighed and stored at 80 8C
before the analysis.euroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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The samples were extracted and purified according to Valle´e and colla-
borators (Valle´e et al., 2000) with minor modification. Briefly, samples
(100 mg/tissue) were added with internal standards and homogenized in
2 ml of MeOH/acetic acid (99:1, v/v) using an ultrasonic homogenizer (Bran-
sonic Ultrasonic Co., USA). After an overnight at 4 8C, samples were cen-
trifuged at 12,000 rpm for 5 min and the pellet was extracted twice with 1 ml of
MeOH/acetic acid (99:1, v/v). The organic phases were combined and dried
with a gentle stream of nitrogen in a 40 8C water bath. The samples were
resuspended with 3 ml of MeOH/H2O (10:90, v/v) and passed through SPE
cartridge, previously activated with MeOH (5 ml) and MeOH:H2O 10:90 (v/v)
(5 ml). The steroids were eluted in MeOH, concentrated and transferred in
autosampler vials before the LC–MS/MS analysis.
2.4. Quantitative analysis and analytical method validation
2.4.1. Calibration curves
Quantitative analysis was performed on the basis of calibration curves daily
prepared and analyzed: blank samples (6% albumin in PBS) were spiked with
D4-17b-E (1 ng/sample), D9-PROG (0.2 ng/sample) and D4-PREG (5 ng/sam-
ple), as internal standards. Increasing amounts (0.05–5 ng/sample) of each
steroid were added. Calibration curves were extracted and analyzed as already
described for samples.
2.4.2. Limit of quantification, precision and accuracy
The limit of quantification (LOQ) was calculated as the lowest amount of
steroid measured with a minimum error of 20% in triplicate, as described by
Valle´e and collaborators (Valle´e et al., 2000).
Inter-assay accuracy and reproducibility of the method were calculated over
a series of blank samples spiked with 0.5, 2.5 and 5 ng/sample and estimated on
the basis of calibration curves. Accuracy was calculated by the ratio (obtained
value/true value  100) in different five samples prepared and injected in
duplicate in different days. Precision was determined as coefficient of variation
(CV%) calculated on the basis of five samples prepared and injected in different
days.
2.5. Statistical analysis
The linearity of the standard curve (r2), the accuracy (%) and the precision
(CV%) inter-series were judged by GraphPad4 PRISM (version 4). Student’s t-
test was used to determine significant differences between control and diabetic
tissues.
3. Results
The present approach is based on the power of tandem mass
spectrometry. The increase of specificity (also reflecting anUN
COTable 2Validation of the methodr2 LOQ (pg/sample) Level 0.5
Accuracy (%) Precision CV%
PREG 0.999 0.05 96 11.91
PROG 0.990 0.05 105 12.23
DHP 0.990 0.25 101 22.06
THP 0.998 0.1 93 0.56
T 0.999 0.02 109 8.06
DHT 0.992 0.05 102 9.61
3a-Diol 0.992 0.05 107 11.07
17a-E 0.999 0.02 105 4.74
17b-E 0.999 0.02 102 3.12
r2: Linearity of the assay calculated on the basis of almost four calibration curve
value  100 (five samples prepared and injected in different days) on the basis of th
injected in different days).
Please cite this article in press as: Caruso, D. et al., Evaluation of n
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improvement of sensitivity) achieved with this method
represents the basis for unambiguous identification of the
analytes. Their structural identification is based not only on the
molecular ion and retention time, but also on specific
fragmentation routes specifically related to the structure.
Therefore, the described method allows the identification and
quantification of PREG, PROG, DHP, THP, T, DHT, 3a-diol,
17a-E and 17b-E in nervous tissues with satisfactory standards
of linearity, precision, accuracy and sensitivity (Table 2). The
correlation coefficient values (r2) were greater than 0.99,
indicating an adequate linearity of our analytical procedure. As
shown in this table, accuracy and reproducibility were within
the accepted tolerances even at the lowest concentration level
studied (93–108%; CV%<15). As expected, the highest values
were obtained at the lower concentrations and for DHP, for
which the LOQ is very high due to a difficulty in the ionization.
Fig. 1 shows representative examples of ion chromatograms
and the mean of five calibration curves prepared and analyzed
in different days. In the first segment of the analysis (14–
18 min, panel A) 17a-E, 17b-E and T were detected. These
compounds were quantified using D4-17b-E as internal
standard; the linearity of the determinations was presented in
the right part of the panel A. Similarly, panels B and C show the
second (18–32 min) and the third (32–47 min) segments of the
analysis and the respective calibration curves. All the
compounds were discernible on the basis of different ion
and/or retention times.
Fig. 2 shows the levels of neuroactive steroids in cerebellum
of control and STZ-treated rats. All neuroactive steroids
analyzed, with the exception of 17a-E, were identified and
measured in control animals. A significant impact of three
months of diabetes was evident. In particular, PREG, PROG
and T levels were significantly decreased in cerebellum of STZ-
treated rats. On the contrary, metabolites of PROG (i.e., DHP
and THP) or of T (i.e., DHT and 3a-diol) as well as the levels of
17b-E were unaffected by diabetes. A different pattern of
steroid levels in control and STZ-rats was present in the other
two CNS regions analyzed. In particular, as shown in Fig. 3,
only PREG, PROG, Tand its derivatives (i.e., DHTand 3a-diol)
were detected in the cerebral cortex of control animals. AmongLevel 2.5 Level 5
Accuracy (%) Precision CV% Accuracy (%) Precision CV%
100 6.71 101 1.79
98 6.97 101 1.85
102 7.80 100 2.58
96 0.16 101 0.44
102 5.45 100 0.64
100 3.90 100 1.67
94 4.58 101 1.83
102 2.79 100 0.65
102 2.78 99 0.67
s; LOQ: limit of quantification; accuracy is calculated as obtained value/true
e calibration curves; precision is calculated as CV% (five samples prepared and
euroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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Fig. 1. Representative LC–MS/MS chromatogram of a standard sample. The identity of each peak is based on the retention time and MS/MS spectra of authentic
compounds. Calibration curves were prepared as described in Section 2. Data are expressed as mean  S.E.M. (n = 5). (Panel A) Left: first segment of the analysis
(13–18 min) 17a-E and 17b-E, T and D4-17b-E as internal standard; right: corresponding calibration curves. Panel (B) left: second segment of the analysis (18–
32 min) DHT, PROG, 3a-diol and D9-PROG as internal standard; right: corresponding calibration curves. (Panel C) Left: third segment of the analysis (32–47 min)
PREG, THP, DHP and D4-PREG as internal standard; right: corresponding calibration curves.
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Cthese, only the levels of PROG, Tand 3a-diol were significantly
decreased by diabetes. The levels of DHT observed in the
cerebral cortex of STZ-treated rats were under the detection
limit, but not significantly different from those observed in
control rats. It is interesting to note that in the cerebral cortex of
both control and diabetic rats, the levels of DHP, THP, 17a-E
and 17b-E were under the detection limit.
Most steroids analyzed were detected and measured in the
spinal cord of control and diabetic animals, with the exception
of DHP, 17a-E and 17b-E (Fig. 4). PROG, DHT and 3a-diol
were significantly decreased in the spinal cord of diabetic
animals, while PREG, T, and THP were unaffected by diabetes.
Interestingly, the levels of 17b-E, which were under thePlease cite this article in press as: Caruso, D. et al., Evaluation of n
spectrometry in central and peripheral nervous system: Effect of diabetdetection limit in the spinal cord of control animals, were
detectable in diabetic animals.
As shown in Fig. 5, brachial nerves of control animals
showed detectable levels of all neuroactive steroids and the
impact of diabetes was evident with most of them, with the
exception of PROG, 17a-E and 17b-E. In particular, PREG,
DHP, THP, T, DHTand 3a-diol levels decreased significantly in
brachial nerve of diabetic animals.
4. Discussion
The advent of robust and analytically reliable techniques
based on the combination of liquid chromatography (LC) andeuroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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Fig. 2. Effect of diabetes on the levels of neuroactive steroids in the cerebellum. Data are expressed as pg/mg tissue  S.E.M. (number of determinations in each
group in parentheses). LOQ: limit of quantification (see Table 2 for details). *p < 0.05, ***p < 0.005 vs. control (CTRL).
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mass spectrometry (MS) by means of atmospheric pressure
ionization (API) (e.g., electrospray, ESI and atmospheric
pressure chemical ionization, APCI) and in particular the
improvements brought about by tandem MS (MS/MS), has
opened new perspectives in terms of mass spectrometric
identification and quantification of steroids that are difficult to
analyze by gas chromatography–MS. With respect to the
ionization mode, APCI is mainly applied to rather less polar
compounds than ESI but is less susceptible to ion suppression
due to the presence of several interferences as is the case in
biological tissues. For quantitative assays employing MS
detection, triple quadrupole systems are most commonly used,
while the new generation of ion trap, namely the linear trap,
exhibits similar performance, as also demonstrated by our
results. In addition, when an APCI-linear trap is operated in the
MS/MS mode, the identification and quantification of the
analytes are based on both precursor and product ions, giving
higher selectivity and better sensitivity than for any other MS
system. Based on these factors, we set up the analytical method
reported here, which permitted to simultaneously measure
several neuroactive steroids in cerebral cortex, cerebellum,
spinal cord and brachial nerve. Data obtained have indicatedPlease cite this article in press as: Caruso, D. et al., Evaluation of n
spectrometry in central and peripheral nervous system: Effect of diabetthat these nervous structures did not show the same pattern of
distribution of the neuroactive steroids under consideration. For
instance, it is interesting to note that only the brachial nerve
showed the presence of all these neuroactive steroids (i.e.,
PREG, PROG, DHP, THP, T, DHT, 3a-diol, 17a-E and 17b-E).
In the central nervous system, the cerebellum showed
detectable levels of all these neuroactive steroids with the
exception of 17a-E. In contrast, the cerebral cortex seems to be
unable to produce or accumulate PROG metabolites (i.e., DHP
and THP) as well as 17a-E and 17b-E. A similar pattern is
evident in the spinal cord, where DHP, 17a-E and 17b-E were
under detection limits. Levels of PROG metabolites as well as
of 17a-E and 17b-E in cerebral cortex and spinal cord are in
apparent disagreement with observations available in the
literature indicating that these two nervous structures seem to
express the enzymes producing PROG metabolites (i.e., 5a-
reductase and 3a-hydroxysteroid dehydrogenase (Melcangi
et al., 1987; Stoffel-Wagner, 2003; Patte-Mensah et al., 2004;
Agis-Balboa et al., 2006) and converting T into estrogens (i.e.,
aromatase) (Evrard and Balthazart, 2003; Stoffel-Wagner,
2003; Yague et al., 2006). The discrepancy between the local
levels of steroids and the local expression of steroidogeniceuroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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Fig. 3. Effect of diabetes on the levels of neuroactive steroids in the cerebral cortex. Data are expressed as pg/mg tissue  S.E.M. (number of determinations in each
group in parentheses). LOQ: limit of quantification (see Table 2 for details). *p < 0.05, **p < 0.02, ***p < 0.005 vs. control (CTRL).
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enzymes suggests that PROG metabolites and estrogens are
rapidly cleared in the cerebral cortex and the spinal cord. In
addition, levels of expression of steroidogenic enzymes may
not necessarily reflect their levels of activity.
The results reported here also indicate that diabetes, induced
by injection with STZ, strongly affects the levels of neuroactive
steroids. Generally a decrease both in the CNS and PNS was
observed. In some cases the effects of diabetes on steroid levels
in neural tissue did not completely reflect the changes
previously reported in plasma. For instance, the levels of
PREG in the brachial nerve and cerebellum of diabetic rats
reported here show a significant decrease, but remain
unchanged in plasma (Leonelli et al., 2007). These findings
suggest that diabetes differentially alters steroid synthesis in
endocrine glands and nervous structures. Indeed, formation of
PREG and other steroids in the peripheral and central nervous
systems is not surprising. It has been clearly established that
glial cells of the peripheral and central nervous systems express
molecules, such as translocator Protein-18 kDa (TSPO,
formerly known as peripheral benzodiazepine receptor) and
steroidogenic acute regulatory protein, able to participate in the
transport of cholesterol to the inner mitochondrial membrane
where cytochrome P450scc (i.e., the enzyme forming PREG) isPlease cite this article in press as: Caruso, D. et al., Evaluation of n
spectrometry in central and peripheral nervous system: Effect of diabetlocated (Garcia-Segura and Melcangi, 2006). An altered
neurosteroidogenesis has been also observed in different forms
of neural injury and different neuropathological conditions. For
instance, TSPO basal expression is upregulated in gliomas, in
neurodegenerative disorders, and in various forms of brain
injury and inflammation (Papadopoulos et al., 2006). A very
similar effect occurs in the PNS, where the expression of TSPO
is increased in Schwann cells after nerve lesion and returns to
normal levels when regeneration is completed (Lacor et al.,
1999). This induction has been interpreted as reflecting an
endogenous increase in steroidogenesis as a neuroprotective
response to the damage. In agreement with that, an increased
biosynthesis of PROG has been detected in the spinal cord of
diabetic animals using HPLC combined with a continuous flow
scintillation detection method (HPLC-Flo/one method) utiliz-
ing exogenous substrate (tritiated PREG) to evaluate PROG
formation (Saredi et al., 2005). It is clear that the endogenous
mechanism triggered by diabetes is certainly not enough to
protect the nervous system efficiently. Furthermore, although
PROG biosynthesis is increased, we demonstrate here that
PROG levels are decreased in spinal cord of diabetic animals,
suggesting an increased PROG metabolism. In this regard it is
also important to note that while the levels of PROG areeuroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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diabetes, further suggesting an enhanced PROG metabolism in
the spinal cord of diabetic animals.
The decrease of the levels of several neuroactive steroids
associated with diabetes is also interesting in relation with the
protective effect exerted by some of these molecules.
Indeed, recent observations have shown that neuroactive
steroids might provide a new therapeutic tool for damage
induced by diabetes both in PNS and CNS. For instance,
dehydroepiandrosterone prevents vascular and neuronal dys-
function in the sciatic nerve of STZ-treated rats (Yorek et al.,
2002). In the same experimental model, we recently observed
that PROG and its derivatives, DHP and THP, reversed the
impairment of nerve conduction velocity and thermal threshold,
restored intra-epidermal nerve fiber density, improved Na+,K+-
ATPase activity, and counteracted the decrease of gene
expression of myelin proteins, such as glycoprotein zero and
peripheral myelin protein 22 (Leonelli et al., 2007). We alsoPlease cite this article in press as: Caruso, D. et al., Evaluation of n
spectrometry in central and peripheral nervous system: Effect of diabetobserved that PROG or DHP administration results in a
significant reduction in the number of fibers with myelin
abnormalities in the sciatic nerve of STZ-treated rats (Veiga
et al., 2006).
Neuroactive steroids are also protective against detrimental
effects of diabetes mellitus on the CNS. For instance, estrogens
can increase the regional brain glucose utilization in diabetic
(db/db) mice (Garris, 1999). Moreover, as demonstrated in
STZ-rats, treatment with 17b-E may have a beneficial effect in
dementia disorders associated with diabetes (Lannert et al.,
1998), and, as demonstrated in Bio Breeding (BB) diabetic rats,
decreases the infarct size after temporary focal ischemia (Toung
et al., 2000). Furthermore, it has been recently demonstrated
that 17b-E stimulates brain neurogenesis and exerts protective
effects at hippocampus level in STZ mice (Saravia et al., 2006).
In conclusion, the data reported here demonstrate that the
LC–MS/MS method described allows the assessment of
neuroactive steroids in structures of CNS and PNS with higheuroactive steroid levels by liquid chromatography–tandem mass
es, Neurochem. Int. (2007), doi:10.1016/j.neuint.2007.06.004
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sensitivity and specificity. By means of this methodological
procedure, we observed that diabetes strongly affects the levels
of several neuroactive steroids in the CNS and PNS. This
finding provides a further basis for the proposal of a therapeutic
strategy based on neuroactive steroids aimed at counteracting
the neurodegenerative effects of diabetes.
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